New Chart Pack: Biopharmaceuticals in Government Programs

PhRMA released a new resource on biopharmaceuticals in government programs. This new chart pack features key facts about prescription medicines in four government programs – Medicare, Medicaid, Veterans Affairs and the 340B drug discount program.

Allyson Funk
Allyson FunkJuly 16, 2015

New Chart Pack: Biopharmaceuticals in Government Programs

Today, PhRMA released a new resource on biopharmaceuticals in government programs. This new chart pack features key facts about prescription medicines in four major government programs – Medicare, Medicaid, Veterans Affairs and the 340B drug discount program.

Check out the chart pack here: http://www.phrma.org/gov-chartpack-2015

Below is a preview of the new resource.

Federal Spending on Health Care
Over the Next Decade:

fed-spending-healtchare

 

Medicines in Medicare Part D
Beneficiaries Save Through Plan Competition and Manufacturer Negotiations

beneficiaries-save

 

Medicines in Medicare Part B
Program Spending on Prescription Medicines Accounted for About 8% of Part B Spending in 2012

part-b-expenditures

 

Medicines in Medicaid
On Average, About 60% of the Initial Cost of Brand Medicines is Returned to States Through Rebates

 

medicaid_costs

Medicines in Veterans Affairs
VA Formulary Covers Fewer Drugs Than Part D

va-formularies

Medicines in 340B
Without Significant Reforms 340B Will Continue to Grow as Uninsured Rate Declines

uninsured-declines

Check out PhRMA’s other chart pack resources here and check back with our Medicare Monday series and 340B Spotlight as we take a deeper look at some of these charts in the coming weeks.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.